In the News: Health Care Heroes Award

ivWatch Chief Medical Officer, Dr. Brian Clare, was named a 2019 Health Care Hero for the ‘Innovations in Health Care’ category. Read more on this special report by Inside Business here.

ivWatch Chief Medical Officer Gains Health Care Hero Title

Brian Clare, M.D. recognized for business pursuits and philanthropic efforts

HAMPTON, Va., March 4, 2019 – Brian Clare, M.D. chief medical officer and member of the Board of Directors at ivWatch, a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, gained recognition as an Inside Business 2019 Health Care Hero during the publication’s annual breakfast March 4 at Norfolk Waterside Marriott. Dr. Clare was recognized as the winner in the ‘Innovations in Health Care’ category for his efforts during his long-standing medical career as an emergency medicine physician and for his work locally helping companies gain critical access to resources.

“Dr. Clare is all business when it comes to medicine,” remarked program judge Kathryn Barrett of Barrett Communications and former WVEC-TV medical editor.

The Health Care Heroes awards epitomize the spirit embodied in the word “hero” in the delivery of health care in the Hampton Roads community; Clare’s reach extends far beyond. Notable achievements include creating one of the first Scribe companies in the United States helping physicians with documentation overburden, and helping secure regulatory clearance for the ivWatch Model 400, a medical device that offers hospitals and health care facilities a means to protect patients from a common complication of IV therapy.

“Brian has been very entrepreneurial in medicine and on the leading edge of developing new markets to correct health care inefficiencies,” said Gary Warren, president and CEO of ivWatch. “Brian’s guidance has been instrumental in helping us secure many of our most important milestones.”

In addition to his advisory roles at ivWatch and other organizations based in Hampton Roads, Clare leads the board of Richmond-based non-profit World Pediatric Project as Chairman, providing life-saving care for critically ill children in the Caribbean and Central America.

To learn more about ivWatch and their leadership team, visit https://www.ivwatch.com/about-us/.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

Infusion Nurses Society Leader Discusses Improving Care with ivWatch CEO

Pioneering efforts to address a common IV therapy complication brought into focus at upcoming association programs

HAMPTON, Va., February 6, 2019 – Several nursing associations have incorporated ivWatch representatives and customers in educational programming to present the latest advances in using sensor technology to identify peripheral IV infiltration/extravasation events earlier than ever before to reduce patient injury.

The Infusion Nurses Society (INS) ‘Talking in Vein’ podcast series is part of the association’s learning center and a forum to discuss infusion-related topics with clinical experts, patient advocates and industry leaders. Launching today is a show with guests Mary Alexander MA, RN, CRNI, CAE, FAAN, CEO of Infusion Nurses Society and Gary Warren, president and CEO of ivWatch. The podcast, “Infiltration: Not What We Thought It Was,” reviews misconceptions about IV failure. During the show Warren discusses how technology can impact and provide better clinical outcomes but asserts it should not replace clinical critical thinking.

In her final remarks, Alexander concludes, “It’s helpful that devices such as ivWatch will warn us of an impending infiltration, however I can’t stress enough the importance of nursing assessment and patient feedback. I do believe there is a nice marriage between practice and technology, and I think it’s important that we’ve got the right balance with the two.”

The discussion showcases the willingness of professional associations and medical device manufacturers to work together to review the real-world implications of novel technology. Additional upcoming events where experts will share their work combating the potential for injury from peripheral IV infiltration/extravasation include:

  • On February 13, Gregory Schears, MD, a pediatric intensivist and anesthesiologist at the Mayo Clinic will facilitate a live webinar session “Short Peripheral Catheter Infiltration: Minimizing Risks to Improve Outcomes,” hosted by the Infusion Nurses Society.
  • On April 25, vascular access leaders from Cincinnati Children’s Hospital Medical Center, Sylvia Rineair MSHA, BSN, RN, VA-BC and Darcy Doellman MSN, RN, CRNI, VA-BC, will speak at the 2019 American Nurses Association (ANA) Quality and Innovation Conference. They will discuss a quality improvement project including clinical studies and deployment of ivWatch technology to reduce patient harm from peripheral IV complications during the concurrent session “Improving the Safety of Peripheral IVs with Novel Technology.” 
  • On April 26, ivWatch Chief Nursing Officer (CNO), Susan Brown joins Jamie Carter BSN, RN, patient care services director at Children’s Hospital of the Kings Daughters at the Society of Pediatric Nurses (SPN) 29th Annual Conference. The joint podium presentation will review how the institution reduced severe peripheral IV infiltration/extravasation events through nurse education and ivWatch technology.

Through educational initiatives like these along with sponsorship of the platform myIV.com, ivWatch showcases continued commitment to improving patient safety and outcomes. To learn more about ivWatch and upcoming event participation, visit www.ivWatch.com/events/.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Announces Additional Global Distribution Partner

HAMPTON, Va., December 11, 2018 – ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently entered into a distribution agreement with Sedeer Medical Services. Sedeer Medical Services is a major provider and distributor of medical and health care products in Qatar.

“Qatar’s health sector has an exceptional international reputation for offering quality medical care,” said Babu Kupparayil, managing director at Sedeer Medical. “We’re eager to help institutions meet their health care visions by offering the most advanced technology allowing better patient outcomes during IV therapy.”

Upon completion of regulatory approval requirements, Sedeer Medical will distribute and provide training and support for the ivWatch Model 400 patient monitor to new customers as the exclusive distributor in Qatar.

“With a joint mission of working to set new standards of care in the field of quality health care, we are confident Sedeer Medical will be successful in introducing ivWatch breakthrough technology to hospitals and facilities in search of the best solution for early detection of peripheral IV leakage,” said Scott Hensley, vice president of sales and business development at ivWatch.

For further information about ivWatch and their industry partners, visit  www.ivwatch.com/about-us/partnerships/.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Grows Global Intellectual Property Portfolio with Additional Patent Grants

Australian and Japanese grants bring owned patents to nine

HAMPTON, Va., December 5, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently had two patent applications granted by the Australian and Japanese Patent Offices expanding the company’s intellectual property (IP) portfolio. ivWatch now owns nine patents around the world corresponding to their proprietary breakthrough technologies.

The granting of Australian Patent No. 2013257212 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be independent of the dressings that cover infusion sites during IV therapy or integrated within. This Australian grant comes on the heels of the company announcing an Australia and New Zealand distribution agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories.

“Our research and development efforts allow us to continually innovate,” said Gary Warren, president and CEO of ivWatch. “Protecting the resulting breakthroughs of those efforts as we expand into new markets ensures patients have highly effective early detection technology no matter where they are receiving medical treatment.”

ivWatch patented technology addresses patient harm caused by peripheral IV infiltration and extravasation events head-on, something many medical device companies and health care systems have attempted over the past 30 years. ivWatch succeeded by solving motion issues related to continuous peripheral IV therapy monitoring.

This core technology is related to ivWatch’s fourth Japanese patent grant, Registration No. 6396904, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. By mitigating the effects of changing tissue blood volume, the system minimizes “false” notifications. Reliable early detection of these events paves the way for a new standard of care to minimize injuries associated with the common complication of IV therapy.

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

 

ivWatch Announces Two Senior Executives to Strengthen Growth

New roles include finance and research & development department leaders

HAMPTON, Va., November 27, 2018 – ivWatch, a medical device and biosensor technology company specializing in continuous monitoring solutions for the early detection of intravenous (IV) infiltrations and extravasations, is pleased to announce two new additions to its executive leadership team with the appointments of Nikki Lowe as chief financial officer and Jaclyn Lautz, Ph.D. as vice president of research & development. These executive and senior leadership positions will strengthen the company’s focus on global growth and increase the pace of their biosensor platform development.

“We’re thrilled to have two talented senior executives join our mission to keep more patients safe from preventable medical harm,” said Gary Warren, president and CEO of ivWatch. “Nikki and Jaclyn both have perfectly suited skills and insights to jump in and build their strategies supporting our roadmap and continued investment in new health care innovations.”

Nikki Lowe, Chief Financial Officer

As a member of the company’s executive management team and a direct report to President and CEO Gary Warren, Lowe will have primary responsibility for planning, implementing, managing and controlling all financial-related activities of the company. This will include accounting, finance, forecasting, strategic planning and manufacturing financial analysis.

Lowe has successfully led diverse global accounting functions for multi-divisional companies. She has more than 10 years of executive leadership experience, which includes mergers and acquisitions, financial operations, investor relations and strategic planning reporting and analysis in software and consumer industries. Most recently, she served as an Executive Vice President of Finance for Perfect Commerce Holdings, a global sourcing and procurement software solutions company that she helped facilitate its sale to a UK public entity.

Prior to that role, Lowe served in various accounting and finance leadership roles at top companies in Newport News, Va. including Spiegel, Newport News and Shape FX brands and Ferguson Enterprises. A certified public and global management accountant, Lowe also held senior associate positions in her early career at KPMG and Clifton Gunderson after receiving a bachelor’s degree in accounting from the University of Illinois in Springfield.

Jaclyn Lautz Ph.D., Vice President, Research & Development

As a senior leader, Lautz will oversee all product development and innovation efforts for the company. Her role in this new position includes directing the engineering teams on the design and development of new products and working across departments to bring new products to the market. She will also report directly to Warren.

Lautz rejoins ivWatch from Pricewaterhouse Coopers (PwC) where she was an advisory manager in the pharmaceutical and life sciences operations practice. From 2014-2017, Lautz was ivWatch’s Director of Regulatory Affairs & Quality Assurance, where she was involved with nearly every department in the company from research and development to post-market surveillance. Previous career experiences include six years working as an engineering innovation fellow at Applied Research Associates, a scientific research and engineering company, a biomedical engineer at Semprus Biosciences and a software engineer at an orthopedic clinic.

Lautz has a Ph.D. in mechanical engineering & materials science from Duke University where she worked with industry partners, Siemens and Boston Scientific, on new medical devices and treatment strategies for urological diseases. She holds a B.S. in biomedical engineering from Boston University. Her work is published in several physics and medical journals.

To learn more about ivWatch leadership, visit www.ivwatch.com/about-us/#leadership-team.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. www.ivwatch.com

MEDIA CONTACT

Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest